Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA
3163 covers NAION (vision loss) claims related to semaglutide Eligible claimants are individuals who used Ozempic, Wegovy, or Rybelsus and suffered serious gastrointestinal or ophthalmic injuries No global settlement has been reached as of the date of this publication
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution
A dual GLP-1 and GIP receptor agonist, such as tirzepatide, stimulates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors
These complications relate to the pharmacological effects of GLP-1 receptor activation rather than the route of administration, so delivery method does not substantially change their incidence
Understanding your peptide genetic profile alongside your cardiovascular biomarkers can support a more personalized discussion with your provider about GLP-1 eligibility, expected benefits, monitoring frequency, and whether compounded GLP-1 options (semaglutide or tirzepatide) align with your individual health trajectory
